94 related articles for article (PubMed ID: 14520428)
21. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
[TBL] [Abstract][Full Text] [Related]
22. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
[TBL] [Abstract][Full Text] [Related]
23. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
[TBL] [Abstract][Full Text] [Related]
24. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
[TBL] [Abstract][Full Text] [Related]
28. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
[TBL] [Abstract][Full Text] [Related]
29. Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide.
Kim SY; Lee JW; Lim J; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Kim CC
Biol Blood Marrow Transplant; 2007 Jul; 13(7):863-70. PubMed ID: 17580265
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
[TBL] [Abstract][Full Text] [Related]
31. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
[TBL] [Abstract][Full Text] [Related]
32. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
[TBL] [Abstract][Full Text] [Related]
33. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation.
Elmaagacli AH; Koldehoff M; Hindahl H; Steckel NK; Trenschel R; Peceny R; Ottinger H; Rath PM; Ross RS; Roggendorf M; Grosse-Wilde H; Beelen DW
Transplantation; 2006 Jan; 81(2):247-54. PubMed ID: 16436969
[TBL] [Abstract][Full Text] [Related]
34. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
Bartsch K; Al-Ali H; Reinhardt A; Franke C; Hudecek M; Kamprad M; Tschiedel S; Cross M; Niederwieser D; Gentilini C
Transplantation; 2009 Jan; 87(2):217-21. PubMed ID: 19155975
[TBL] [Abstract][Full Text] [Related]
35. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation.
Wirk B; Klumpp TR; Ulicny J; Herman JH; Gajewski JL; Martin ME; Emmons RV; Mangan KF
Transfusion; 2008 Jan; 48(1):163-8. PubMed ID: 17900280
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
[TBL] [Abstract][Full Text] [Related]
37. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
[TBL] [Abstract][Full Text] [Related]
38. Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD.
Weston LE; Geczy AF; Briscoe H
Bone Marrow Transplant; 2006 Jan; 37(2):207-12. PubMed ID: 16284610
[TBL] [Abstract][Full Text] [Related]
39. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation.
Stark GL; Dickinson AM; Jackson GH; Taylor PR; Proctor SJ; Middleton PG
Transplantation; 2003 Dec; 76(12):1742-9. PubMed ID: 14688526
[TBL] [Abstract][Full Text] [Related]
40. The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors.
Pabst C; Schirutschke H; Ehninger G; Bornhäuser M; Platzbecker U
Clin Cancer Res; 2007 May; 13(10):2916-22. PubMed ID: 17504991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
